Market Scenario:
Arthritis means inflammation in a joint. The inflammation is characterized by swelling, pain, and redness within the joint. This type of arthritis is known to cause chronic inflammatory disorder in the hands and feet.
There are two types of rheumatoid arthritis are seronegative rheumatoid arthritis and seropositive rheumatoid arthritis. Smoking and family history are considered as some of the major cause of rheumatoid arthritis.
The rising R&D of product pipeline along with the introduction of novel products are some of the major trends in this market. For instance, in February 2016, Pfizer received FDA approval for commercialization of XELJANZ XR (tofacitinib citrate) in the U.S. market. The company launched the product in Europe for the treatment of rheumatoid arthritis. In May 2017, Sanofi received FDA approval for Kevzara drug for its commercialization in the U.S. market. Kevzara is used in the treatment of active rheumatoid arthritis.
Get Premium Sample Copy of Seropositive Rheumatoid Arthritis Drug Market Report spread across 90 Premium Pages, 19 Companies and Supported with 73 Tables and 43 Figures is Now Available at: https://www.marketresearchfuture.com/sample_request/5572
The global seropositive rheumatoid arthritis drug market is expected to be driven by factors such as rising cigarette consumption, growing healthcare expenditure, increasing female population, and increasing obese population. However, the growth of this industry is hindered by increasing treatment costs and high cost associated with R&D. The global seropositive rheumatoid arthritis drug market is rather concentrated with few pharmaceutical companies dominating the market through new drug approval.
The global seropositive rheumatoid arthritis drug market is expected to grow at a CAGR of approximately 4.0% during the forecast period 2017-2023.
Intended Audience
- Seropositive Rheumatoid Arthritis Drug Suppliers
- Seropositive Rheumatoid Arthritis Drug Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Segmentation
The global seropositive rheumatoid arthritis drug market is segmented on the basis of the drug class, drug, treatment and diagnosis, route of administration, application, and end user.
On the basis of the drug class, the global seropositive rheumatoid arthritis drug market is segmented into Non-steroidal anti-inflammatory drug type (NSAID), Steroids, and Disease-modifying anti-rheumatic drug type (DMARDs) and biologic agents.
On the basis of the drug, the global seropositive rheumatoid arthritis drug market is segmented into Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Rituxan (rituximab), Actemra (tocilizumab), Orencia (abatacept), and others.
On the basis of the treatment, the global seropositive rheumatoid arthritis drug market is segmented into synovectomy, tendon repair, joint fusion, and total joint replacement.
On the basis of the diagnosis, the global seropositive rheumatoid arthritis drug market is segmented into C -reactive protein (CRP) Test, CCP, ESR (Erythrocyte Sedimentation Rate) Test and Synovial Fluid Analysis.
On the basis of the route of administration, the global seropositive rheumatoid arthritis drug market is segmented into oral, subcutaneous, intravenous, and others.
On the basis of the application, the global seropositive rheumatoid arthritis drug market is segmented into medicine, scientific research, and others.
On the basis of the end user, the global seropositive rheumatoid arthritis drug market is segmented into hospital, diagnostic centers, ambulatory surgical centers, and others
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Treatment Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
Report with Discount Available @ https://www.marketresearchfuture.com/check-discount/5572
Key Players
Some of key the players in the global seropositive rheumatoid arthritis drug market are Abbott Laboratories (U.S.), Johnson & Johnson Limited (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen (U.S.), Vertex Pharmaceuticals Incorporated (U.S), Sanofi-Aventis (France), AstraZeneca (U.K), Cadila Healthcare Ltd. (India), GlaxoSmithKline Inc. (U.S.), Merck and Co. Inc. (U.S.), and others
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Your information will never be shared with any third party.